secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001193125-26-112338
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA Royalty reports 2025 net income $31.7M vs loss $13.8M; royalties up 68% YoY
--------------------------------------------------------------------------------

- Full-year cash receipts $50.5M ($33.6M royalties, +68% YoY; $16.9M milestones); Q4 net income $6.1M vs loss $4.0M YoY.
- Repurchased 648,048 shares for $16.0M; completed seven acquisitions adding 22 assets to portfolio.
- Pipeline catalysts: volixibat Phase 2b data in PSC in Q2 2026; ersodetug Phase 3 data in tumor HI 2H 2026.
- Seralutinib Phase 3 PAH missed primary endpoint; path forward discussions with FDA ongoing.
- Litigation vs Janssen over TREMFYA IP continues; G&A includes $1.1M legal costs in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312526112338/0001193125-26-112338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312526112338/d34671d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-112338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer